Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of injectable NAD+ at different doses for ovarian function decline
CTR20261623Phase 2Active
- Sponsor
- Chengdu Kangnuo Biopharmaceutical
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide adenine dinucleotide in ovarian dysfunction, Diminished Ovarian Reserve (DOR), sponsored by Chengdu Kangnuo Biopharmaceutical. Started May 2026; status: active.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
ovarian dysfunctionDiminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on CTR20261623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261623.